---
title: 'Meeting report: Considerations for trial design and endpoints in licensing
  therapeutic HPV16/18 vaccines to prevent cervical cancer'
date: '2024-07-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39004526/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240715181450&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Cervical cancer is a major cause of morbidity and mortality globally
  with a disproportionate impact on women in low- and middle-income countries. In
  2021, the World Health Organization (WHO) called for increased vaccination, screening,
  and treatment to eliminate cervical cancer. However, even with widespread rollout
  of human papillomavirus (HPV) prophylactic vaccines, millions of women who previously
  acquired HPV infections will remain at risk for progression to cancer for decades
  to come. ...
disable_comments: true
---
Cervical cancer is a major cause of morbidity and mortality globally with a disproportionate impact on women in low- and middle-income countries. In 2021, the World Health Organization (WHO) called for increased vaccination, screening, and treatment to eliminate cervical cancer. However, even with widespread rollout of human papillomavirus (HPV) prophylactic vaccines, millions of women who previously acquired HPV infections will remain at risk for progression to cancer for decades to come. ...